Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of the APW-RSV II clinical trial is to evaluate if the addition of azithromycin to routine bronchiolitis care, among infants hospitalized with RSV bronchiolitis, reduces the occurrence of recurrent wheeze during the preschool years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis

NCT01486758

RSV Bronchiolitis

COMPLETED PHASE2

Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children

NCT02707523

Respiratory Syncytial Virus

COMPLETED PHASE2

AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department

NCT04669288

Asthma Wheezing

TERMINATED PHASE3

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

NCT05026749

Respiratory Syncytial Virus Infections

RECRUITING PHASE3

Trial II of Lung Protection With Azithromycin in the Preterm Infant

NCT00319956

Bronchopulmonary Dysplasia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The APW-RSV II clinical trial is a double blind, placebo-controlled, parallel-group, randomized trial, including otherwise healthy 188 participants, ages 1-18 months, who are hospitalized due to RSV bronchiolitis. The study includes active treatment phase with azithromycin or placebo for 2 weeks, and an observational phase for up to 48 months.

The main objective of the APW-RSV II clinical trial is to evaluate if the addition of azithromycin to routine bronchiolitis care, among infants hospitalized with RSV bronchiolitis, reduces the occurrence of recurrent wheeze (RW) during the preschool years.

Study participants will be enrolled during 3 consecutive RSV seasons beginning in Fall 2016. Study participants will be randomized to receive PO azithromycin 10 mg/kg/day for 7 days followed by 5mg/kg/day for additional 7 days, or matched placebo. The primary clinical outcome is the time to the occurrence of a third episode of wheezing. The duration of follow up is 18-48 months, which is determined based on the year in which the participants is recruited: first year recruits will be followed for up to 48 months, while the 3rd year recruits will be followed for at least 18 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Syncytial Virus, Bronchiolitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral azithromycin

Oral Azithromycin

Group Type ACTIVE_COMPARATOR

Oral azithromycin

Intervention Type DRUG

Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days

Placebo

Oral Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo suspension

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral azithromycin

Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days

Intervention Type DRUG

Placebo

Placebo suspension

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Azithromycin suspension

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 1-18 months.
* Hospitalization for the first episode of RSV bronchiolitis.
* Confirmed RSV infection by positive nasal swab results (PCR assay and/or direct antigen detection).
* At least two of the following symptoms/signs of bronchiolitis: respiratory rate greater than 40 breaths/minute; cough; wheezing; audible rales, crackles, and/or rhonchi; paradoxical chest movements (retractions)28.
* Duration of respiratory symptoms from onset of symptoms of the current illness to admission is 120 hours (5 days) or less.
* Randomization can be performed within 168 hours (7 days) from onset of symptoms.
* Willingness to provide informed consent by the child's parent or guardian.

Exclusion Criteria

* Prematurity (gestational age \< 36 weeks).
* Presence or history of other significant disease (CNS, lung, cardiac, renal, GI, hepatic disease, hematologic, endocrine or immune disease). Children with atopic dermatitis and/or food allergy will not be excluded from the study.
* Clinically significant gastroesophageal reflux currently treated with a daily anti-reflux medication (anti- H2 or PPI).
* The child has significant developmental delay/failure to thrive, defined as weight \< 3% for age and gender.
* History of previous (before the current episode) wheeze or previous (before the current episode) treatment with albuterol.
* History of previous treatment with corticosteroid (systemic or inhaled) for respiratory issues.
* Treatment (past or present) with montelukast.
* Treatment with any macrolide antibiotic (azithromycin, clarithromycin or erythromycin) over the past 4 weeks or current treatment with any macrolide antibiotic. Current or prior treatment with non-macrolide antibiotic is not an exclusion criterion.
* Chronic treatment with any daily medication other than vitamins or nutritional supplements. Although routine vitamin D supplement (400 IU per day) is not an exclusion criterion, high dose vitamin D supplements are not allowed.
* Participation in another clinical trial.
* Participant requires invasive mechanical ventilation due to RSV bronchiolitis.
* Evidence that the family may be unreliable or non-adherent, or has definitive plans to move from the clinical center area before trial completion.
* Contraindication of use of azithromycin or any other macrolide antibiotics such as history of allergic reaction (or other adverse reaction) to these antibiotics.
* Diagnosis of asthma.
* Treatment with other medication that may cause QT interval prolongation.

Minimum Eligible Age

1 Month

Maximum Eligible Age

18 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No